Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.40 |
| ▸ | CCND1 | P24385 | 4/20 | 0.40 |
| ▸ | TACR2 | P21452 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HAT1 | O14929 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406987 | 0.91 | TACR2 (0.40) | CDK4CCND1TACR2HTR2AMAPT | |
| SCHEMBL2403278 | 0.90 | TACR2 (0.35) | CDK4CCND1TACR2HTR2AMAPT | |
| SCHEMBL2404564 | 0.90 | TACR2 (0.37) | TACR2HTR2AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL2407217 | 0.89 | TACR2 (0.37) | CDK4CCND1TACR2HTR2AMAPT | |
| SCHEMBL2409274 | 0.87 | TACR2 (0.39) | CDK4CCND1TACR2HTR2AMAPT | |
| SCHEMBL1973164 | 0.86 | HTR6 (0.45) | CDK4CCND1TACR2HTR2AHTR6 | |
| SCHEMBL2406365 | 0.85 | HTR6 (0.46) | CDK4CCND1TACR2HTR2AHTR6 | |
| SCHEMBL2406776 | 0.85 | HTR6 (0.43) | CDK4CCND1TACR2HTR2AHTR6 | |
| SCHEMBL1974366 | 0.84 | HTR6 (0.43) | CDK4CCND1TACR2HTR2AHTR6 | |
| SCHEMBL1974495 | 0.83 | HTR6 (0.41) | CDK4CCND1TACR2HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CDK4 3031/4885CCND1 3178/4885TACR2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.